Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bolstering the FDA's drug-safety authority.

× No keyword cloud information.

12 in total

Review 1. Assessing long-term drug safety: lessons (re) learned from raptiva.

Authors: Nicole M Seminara; Joel M Gelfand
Journal: Semin Cutan Med Surg Date: 2010-03

Review 2. Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis.

Authors: Moshe Vardi; Robert W Yeh; Charles A Herzog; Wolfgang C Winkelmayer; Soko Setoguchi; David M Charytan
Journal: Clin J Am Soc Nephrol Date: 2013-08-22 Impact factor: 8.237

3. Increasing transparency at the FDA: the impact of the FDA Amendments Act of 2007.

Authors: Susan F Wood; Kristen L Perosino
Journal: Public Health Rep Date: 2008 Jul-Aug Impact factor: 2.792

4. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions.

Authors: Anthony Grosso; Ian Douglas; Aroon Hingorani; Raymond MacAllister; Liam Smeeth
Journal: Br J Clin Pharmacol Date: 2008-07-31 Impact factor: 4.335

5. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.

Authors: Daniel M Cook; Rama K Gurugubelli; Lisa A Bero
Journal: Drug Saf Date: 2009 Impact factor: 5.606

6. Off-label use of rituximab in a multipayer insurance system.

Authors: Eliezer M Van Allen; Todd Miyake; Nathan Gunn; Caroline M Behler; Jeff Kohlwes
Journal: J Oncol Pract Date: 2011-03 Impact factor: 3.840

Review 7. Regulating prescription drugs for patient safety: does Bill C-17 go far enough?

Authors: Matthew Herder; Elaine Gibson; Janice Graham; Joel Lexchin; Barbara Mintzes
Journal: CMAJ Date: 2014-03-10 Impact factor: 8.262

8. Quantitative risk-benefit analysis of natalizumab.

Authors: J P Thompson; K Noyes; E R Dorsey; S R Schwid; R G Holloway
Journal: Neurology Date: 2008-07-29 Impact factor: 9.910

9. Off-label prescribing: a call for heightened professional and government oversight.

Authors: Rebecca Dresser; Joel Frader
Journal: J Law Med Ethics Date: 2009 Impact factor: 1.718

10. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.

Authors: Keith B Hoffman; Mo Dimbil; Colin B Erdman; Nicholas P Tatonetti; Brian M Overstreet
Journal: Drug Saf Date: 2014-04 Impact factor: 5.606